Barclays Has Lowered Expectations for DaVita (NYSE:DVA) Stock Price

Key Points

• Barclays has reduced DaVita's target stock price from $169.00 to $160.00, while maintaining an "equal weight" rating, indicating a potential upside of approximately 25.06%.
• DaVita received mixed ratings from analysts, with one sell rating, three hold ratings, and two buy ratings, leading to an average rating of "Hold" and a consensus target price of $165.60.
• In its latest quarterly report, DaVita announced earnings of $2.95 per share, surpassing analysts' expectations and showing a 6.1% increase in revenue year-over-year.

DaVita (NYSE:DVA - Get Free Report) had its target price reduced by stock analysts at Barclays from $169.00 to $160.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an "equal weight" rating on the stock. Barclays's price target would indicate a potential upside of 25.06% from the stock's previous close.

Several other research firms also recently issued reports on DVA. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Truist Financial decreased their price objective on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, DaVita presently has an average rating of "Hold" and a consensus target price of $165.60.

DaVita Stock Up 0.1%

DaVita stock opened at $127.94 on Thursday. The firm has a market capitalization of $9.66 billion, a PE ratio of 12.57, a P/E/G ratio of 0.97 and a beta of 1.09. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.25 and a quick ratio of 1.20. The company's 50-day moving average is $140.32 and its 200-day moving average is $147.34. DaVita has a fifty-two week low of $126.07 and a fifty-two week high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. The company had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 246.39%. The firm's quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.00 EPS. Sell-side analysts anticipate that DaVita will post 10.76 earnings per share for the current year.

Insiders Place Their Bets

In other DaVita news, insider James O. Hearty sold 2,351 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the transaction, the insider directly owned 26,038 shares in the company, valued at $3,905,700. The trade was a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.00% of the stock is currently owned by insiders.

Institutional Trading of DaVita

Several hedge funds and other institutional investors have recently modified their holdings of DVA. Wellington Management Group LLP increased its holdings in DaVita by 9.1% during the 4th quarter. Wellington Management Group LLP now owns 2,711 shares of the company's stock worth $405,000 after acquiring an additional 227 shares during the period. World Investment Advisors bought a new position in shares of DaVita in the 4th quarter worth $222,000. Resona Asset Management Co. Ltd. purchased a new stake in shares of DaVita in the 4th quarter valued at $2,149,000. Aviva PLC boosted its stake in shares of DaVita by 427.7% in the 4th quarter. Aviva PLC now owns 27,921 shares of the company's stock valued at $4,176,000 after purchasing an additional 22,630 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of DaVita by 107.0% in the 4th quarter. Bank of Montreal Can now owns 126,136 shares of the company's stock valued at $18,864,000 after purchasing an additional 65,207 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.